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Introduction: Early prognostication after successful cardiopulmonary resuscitation is difficult, and there is a need
for novel methods to estimate the extent of brain injury and predict outcome. In this study, we evaluated the
impact of the cardiac arrest syndrome on the plasma levels of selected tissue-specific microRNAs (miRNAs) and
assessed their ability to prognosticate death and neurological disability.
Methods: We included 65 patients treated with hypothermia after cardiac arrest in the study. Blood samples were
obtained at 24 hours and at 48 hours. For miRNA-screening purposes, custom quantitative polymerase chain reaction
(qPCR) panels were first used. Thereafter individual miRNAs were assessed at 48 hours with qPCR. miRNAs that
successfully predicted prognosis at 48 hours were further analysed at 24 hours. Outcomes were measured according
to the Cerebral Performance Category (CPC) score at 6 months after cardiac arrest and stratified into good (CPC score 1
or 2) or poor (CPC scores 3 to 5).
Results: At 48 hours, miR-146a, miR-122, miR-208b, miR-21, miR-9 and miR-128 did not differ between the good and
poor neurological outcome groups. In contrast, miR-124 was significantly elevated in patients with poor outcomes
compared with those with favourable outcomes (P < 0.0001) at 24 hours and 48 hours after cardiac arrest. Analysis of
receiver operating characteristic curves at 24 and 48 hours after cardiac arrest showed areas under the curve of 0.87
(95% confidence interval (CI) = 0.79 to 0.96) and 0.89 (95% CI = 0.80 to 0.97), respectively.
Conclusions: The brain-enriched miRNA miR-124 is a promising novel biomarker for prediction of neurological prognosis
following cardiac arrest.Introduction
Sudden cardiac arrest is a cause of substantial mortality
and morbidity that affects more than one million indi-
viduals worldwide every year [1]. Early prognostication
of neurological outcome after successful cardiopulmo-
nary resuscitation using clinical examination alone is dif-
ficult and has become more complicated with the
introduction of therapeutic hypothermia as a treatment
strategy for comatose cardiac arrest patients. Hypothermia
affects the metabolism of sedative drugs, and lingering
sedation has been found to be an important reason for the
decreased reliability of a clinical neurological examination
to predict poor outcome after cardiac arrest, as reported
by several authors [2,3]. Hence, there is a need for novel* Correspondence: patrik.gilje@med.lu.se
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reproduction in any medium, provided the ormethods to estimate the extent of brain injury and predict
outcome. Several circulating biomarkers, such as neuron-
specific enolase (NSE), S100B and neurofilament heavy
chain levels, have been evaluated with regard to prognosis.
These assessments have revealed varying degrees of suc-
cess, and the search for an ideal biomarker continues
[4-6]. The modern approach for prognostication after car-
diac arrest combines a neurological examination compris-
ing neurophysiology, biochemical tests and imaging
several days after the incident [7].
MicroRNAs (miRNAs) are short (18 to 23 nucleo-
tides), noncoding RNAs that have a central role in regu-
lating translation and degradation of mRNAs in the cell
[8]. By complementary base-pairing with the 3′ untrans-
lated region of a specific mRNA, miRNAs suppress gene
expression and affect a wide range of physiologic and
pathologic processes. Some miRNAs have a high degree
of tissue specificity, and more than 2,000 human. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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animal models, cerebral ischemia and reperfusion alter
the tissue expression of several miRNAs that are
known to be associated with modulation of apoptosis
[11,12], promotion of cell death [13] and cell-cycle regula-
tion [14], thereby potentially influencing outcomes.
In recent years, miRNAs have been detected in plasma,
where they are associated with proteins and extracellular
vesicles and have been found to be remarkably stable,
remaining in the circulation for days [12]. Furthermore,
many miRNAs have a high degree of organ specificity,
thus making them suitable markers of organ-selective tis-
sue injury. After organ-related injuries such as myocardial
infarction, hepatitis and stroke, levels of tissue-specific
miRNAs increase in the circulation, thus indicating a role
for miRNAs as clinically useful biomarkers [15-17]. In ani-
mal models, the highly brain-enriched miRNA miR-124
[9] has been put forward as a marker of ischemic brain
damage [17,18], but research on human samples after
brain injury is relatively scarce. Investigators in one study
found a difference in plasma miRNA profiles between
stroke patients and controls as well as between patients
with different stroke aetiologies [19], but the potential role
of miRNAs as prognostic markers for stroke has yet to be
clarified. In the field of cardiac arrest, however, researchers
in a recent study of 28 patients showed that miR-122 and
miR-21 in plasma correlated to long-term prognosis
48 hours after cardiac arrest [20].
Our aim in this study was to evaluate the impact of
the cardiac arrest syndrome on the plasma levels of se-
lected tissue-specific miRNAs and to assess their ability
to accurately prognosticate death and neurological dis-
ability. Researchers in previous studies have focused on
tissue samples taken 48 hours after cardiac arrest, so we
initially assessed this time point. Because of the promis-
ing results of miR-124, this miRNA was further analysed




The study was approved by the Regional Ethical Review
Board at Lund University (411/2004 and 223/2008). In-
formed consent was sought from the patient’s next of
kin or retrospectively from the patient.
Study protocol
A more detailed version of the materials and methods
can be found in the Additional file 1. This study was
performed between June 2003 and March 2008 and in-
cluded unconscious patients resuscitated after cardiac
arrest, regardless of location or initial cardiac rhythm.
Unwitnessed asystole was an exclusion criterion. Com-
puted tomography of the brain was performed liberallyat admission to exclude patients with intracranial bleed-
ing. Serial samples were collected from consecutive pa-
tients treated with hypothermia within 6 hours after
admission and at 24 ± 4 hours and 48 ± 4 hours after ad-
mission. The treatment protocol of this study has been
described in detail elsewhere [4]. Briefly, all patients
were treated with hypothermia for 24 hours at 33 ± 1°C,
followed by rewarming at 0.5°C/h. In patients who
remained unconscious, intensive care was continued for
at least 72 hours after normothermia [21].
All surviving patients were followed up at 6 months
after their cardiac arrest and categorized according to
the five-point Cerebral Performance Category (CPC)
scale: CPC score 1: good cerebral performance, CPC
score 2: moderate cerebral disability, CPC score 3: severe
cerebral disability, CPC score 4: coma and CPC score 5:
death [22]. A CPC score of 1 or 2 at 6 months after car-
diac arrest was considered a good outcome.
Ten patients were randomly selected, and the baseline
levels of miR-124 were compared to those levels in age-
and sex-matched controls (5 women and 5 men in each
group, median ages 72 years in the control group and
73 years in the patient group; P = ns). The control group
consisted of patients who underwent a myocardial perfu-
sion scan because of suspicion of angina pectoris, and
the samples were obtained before the scan. Because out-
come was not correlated to miR-124 at baseline, we did
not stratify the patients according to CPC group. Seven
of the patients belonged to the good outcome group
(CPC score 1 or 2) and three patients to the poor out-
come group (CPC scores 3 to 5).
RNA isolation and cDNA synthesis
The RNA was extracted according to the manufacturer’s
instructions (QIAGEN, Hilden, Germany). RNA was then
isolated with the miRNeasy Mini Kit (QIAGEN). For
normalization purposes, a UniSp RNA Spike-in mix/sam-
ple (Exiqon A/S, Vedbæk, Denmark) was added before
preparation of the samples. cDNA was synthesized with
the miRCURY LNA Universal RT cDNA synthesis kit
(Exiqon) using a fixed volume of RNA preparation in each
reaction according to the manufacturer’s instructions.
When preparing RNA from plasma, the yields are in-
sufficient for proper quantitation with, for example, a
NanoDrop spectrophotometer (Thermo Fisher Scientific,
Wilmington, DE, USA) [23]. Therefore, equal volumes of
RNA preparation, rather than equal RNA amounts, were
used as input in the cDNA synthesis.
Quantitative RT-PCR
Custom quantitative RT-PCR (qRT-PCR) panels, includ-
ing 20 miRNAs, were used for screening purposes accord-
ing to the manufacturer’s instructions (Exiqon) on a
StepOnePlus Real-Time PCR System (Applied Biosystems,







Age, (years) 65 (15 to 82) 72 (14 to 87) ns
Female sex 9 (26%) 14 (47%) ns
Initial rhythm
VT/VF 28 (80%) 19 (63%) ns
Asystole 3 (9%) 7 (23%) ns
PEA 4 (11%) 4 (13%) ns
Witnessed CA 29 (83%) 28 (93%) ns
Bystander CPR 17 (49%) 11 (37%) ns
Out-of-hospital CA 30 (86%) 22 (73%) ns
Time from CA to
ROSC (minutes)
16 (2 to 47) 25 (7 to 110) <0.01
Time from CA to initiation
of hypothermia (minutes)
60 (0 to 330) 70 (45 to 210) <0.05
Time from CA to target
temperature (minutes)
225 (25 to 565) 193 (100 to 430) ns
Primary cardiac cause 28 (80%) 18 (60%) ns
aCA, Cardiac arrest; CPC, Cerebral Performance Category; CPR,
Cardiopulmonary resuscitation; ns, Not significant; PEA, Pulseless electrical
activity; ROSC, Return of spontaneous circulation; VF, Ventricular fibrillation; VT,
Ventricular tachycardia. Values are presented as median (range) or counts
and percentages.
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were normalized against the mean of the spike-in controls
Sp2 and Sp4 to adjust for differences in RNA extraction
and reverse transcription efficiencies, and the results are
expressed relative to the mean of the baseline samples
using the formula 2−ΔΔCt.
qRT-PCR was run using primer sets according to the
protocol of the manufacturer (Exiqon) on the StepOne-
Plus Real-Time PCR System. Whenever possible, the re-
sults are expressed relative to baseline and the spike-in
Sp2 using the 2−ΔΔCt method. When we analysed the dif-
ference in miRNA levels at admission, however, we
expressed the results relative to the spike-in Sp2 using
the formula 2−ΔCt.
Initially, a miRNA-screening trial was performed on
samples obtained at 48 hours after cardiac arrest from
eight randomly selected patients from each of the two
outcome groups. After we reviewed the literature, we
identified 20 plasma miRNAs that we hypothesized
would be of interest in studying the cardiac arrest syn-
drome, which we analysed on the custom panels de-
scribed above. One plate containing tissue from two
patients (one in each CPC category) was excluded be-
cause of a technical failure, and another patient in the
CPC 1 or 2 group was excluded because of inhibition of
the PCR as detected by the spike-in controls, leaving us
with 13 patients for further analysis. After Bonferroni cor-
rections, no significant differences were observed between
the groups for any of the 20 miRNAs (see Additional file 2:
Figure S1). On the basis of the visual inspection of the dis-
tributions and the results reported by Stammet et al. [20],
however, we decided to assess the prognostic properties of
the brain-enriched miR-124, miR-9 and miR-128; the
inflammation-associated miR-146a; the liver-specific miR-
122; the cardiac tissue–specific miR-208b; and the apop-
tosis inhibitor/angiogenesis-associated miR-21 on the entire
cohort. The associated plasma proteins C-reactive protein
(CRP), alanine aminotransferase (ALT) and troponin T
(TnT) were measured. NSE values were gathered from a
previous study of the same patient cohort [4].
Calculations and statistics were performed using
GraphPad Prism 5 software (GraphPad Software La Jolla,
CA, USA) and SPSS version 21 software (IBM SPSS, Inc,
Chicago, IL, USA). Continuous data are presented as
medians and ranges. Categorical variables are given as
percentages. The patients were dichotomised into good
and poor outcome groups according to CPC scores,
using CPC score 1 or 2 as good outcomes and CPC
scores 3 to 5 as poor. The distribution of miRNA levels
in the two groups was assessed using the D’Agostino-
Pearson omnibus normality test. As the data could not
be described by a normal distribution, the two-tailed
Mann–Whitney U test was used to detect differences in
miRNA levels with regard to outcomes. Categoricalvariables were analysed using Fisher’s exact test. The
ability of miR-124 to discriminate between good vs poor
prognosis at 24 h and 48 h was assessed with receiver
operating characteristic (ROC) curve analysis. Correla-
tions were performed using Spearman’s correlation test.
Bonferroni corrections were applied to the P-values.Results
The initial cohort consisted of 92 patients. We excluded 25
patients because of missing samples, and 2 patients were
excluded because of unknown outcomes and/or missing
patient data. In the end, 35 patients with favourable out-
comes (CPC score 1 or 2) and 30 with poor outcomes
(CPC scores 3 to 5) with tissue samples taken at baseline
and 24 hours and 48 hours after cardiac arrest were entered
into the study. The patients’ characteristics are summarized
in Table 1. There were no differences between the outcome
groups with regard to age, sex, initial cardiac rhythm or by-
stander cardiopulmonary resuscitation. Patients with poor
outcomes had a longer time to return of spontaneous circu-
lation and a longer time to initiation of hypothermia com-
pared with those who had good outcomes.
At admission within 6 hours after cardiac arrest, there
were no significant differences in miRNA levels between
the outcome groups (see Additional file 3: Figure S2).
miR-124 levels were already elevated tenfold at admis-
sion in patients compared with age- and sex-matched
Figure 2 A poor outcome was associated with a significant
elevation of microRNA-124 at 48 hours after cardiac arrest. The
horizontal lines represent the medians. CPC, Cerebral Performance
Category scale score; mIR-124, MicroRNA-124. ***P < 0.0001.
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miR-122, miR-208b, miR-21, miR-9 and miR-128 levels
did not differ between the good and poor neurological
outcome groups. In contrast, miR-124 was elevated 24-
fold in patients with poor outcomes compared with those
who had favourable outcomes (P < 0.0001) (Figure 2).
Analysis of ROCs at 48 hours showed an AUC of 0.89
(95% CI = 0.80 to 0.97) (Figure 3). A cutoff of 12 yielded
100% specificity and 63% sensitivity at 48 hours for a poor
neurological outcome.
At 24 hours after cardiac arrest, the levels of miR-124
were 14-fold higher in the poor outcome group than in
the good outcome group (P < 0.0001) (Figure 4). Further-
more, calculation of ROCs for a poor neurological prog-
nosis resulted in an AUC of 0.87 (95% CI = 0.79 to 0.96)
(Figure 5). A cutoff of 44 yielded 100% specificity and
30% sensitivity at 24 hours for a poor neurological out-
come. However, a cutoff of 12 increased sensitivity to
53% while maintaining a specificity of 97% for a poor
neurological outcome.
Analysis of ROC curves for NSE revealed AUCs of
0.90 (95% CI = 0.79 to 1.00) at 48 hours and 0.80 (95%
CI = 0.67 to 0.93) at 24 hours, which are similar to the
results for miR-124. Combining miR-124 and NSE did
not improve diagnostic accuracy (AUC = 0.90 (95% CI =
0.80 to 1.00) at 24 hours and AUC = 0.93 (95% CI = 0.84
to 1.00) at 48 hours).
Levels of miR-124 correlated only moderately to NSE
(r = 0.51 at 24 hours and r = 0.49 at 48 hours). No correl-
ation was found at 48 hours between the immunologic-
ally active miR-146a and CRP. A poor correlation was
found between the cardiac miR-208b and TnT (r = 0.44
at 48 hours). Similarly, miR-122 at admission was only
weakly related to ALT at 24 hours (r = 0.49).Figure 1 Plasma microRNA-124 was already elevated tenfold at
the time of admission in patients compared with controls. The
horizontal lines represent the medians. miR-124, MicroRNA-124.Discussion
The results of our present study indicate that the brain-
enriched miRNA miR-124 is a promising candidate
marker to use in predicting outcomes after cardiac ar-
rest. A cutoff of 12 at 24 hours yielded 97% specificity
and 53% sensitivity for prognostication of CPC scores of
3 to 5, a result which may support its clinical efficacy.
Moreover, miR-124 demonstrated good predictive prop-
erties at 48 hours, at which point a cutoff of 12 yielded
100% specificity and 63% sensitivity for a poor neuro-
logical outcome. As a biomarker of brain damage, miR-
124 has previously been characterized in plasma after
induction of stroke in rodents, but our present study,Figure 3 Receiver operating characteristic area under the curve
of microRNA-124 at 48 hours after cardiac arrest. AUC, Area
under the curve; CI, 95% confidence interval.
Figure 4 Plasma microRNA-124 was significantly elevated in
patients with poor outcomes at 24 hours after cardiac arrest.
The horizontal lines represent the medians. CPC, Cerebral Performance
Category scale score; mIR-124, MicroRNA-124. ***P < 0.0001.
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124 has been associated with brain injury in humans.
miR-124 was comparable to NSE with regard to prog-
nostication, and combining the two biomarkers did not
improve diagnostic accuracy.
Our findings are of importance because early prog-
nostication after cardiac arrest is difficult, mainly due
to the liberal use of sedatives, analgesics and muscle
relaxants. The previously accepted time point for prog-
nostication—72 hours after cardiac arrest—is no longer
valid, because, owing to the lingering effects of sed-
ation, the reliability of the neurological examination
cannot be assured [2,3]. Therefore, additional methods
by which to assess the extent of brain injury areFigure 5 Receiver operating characteristic area under the curve
of microRNA-124 at 24 hours after cardiac arrest. AUC, Area
under the curve; CI, 95% confidence interval.needed. Ideally, these methods should be independent
of each other, inexpensive, easily interpreted and with-
out significant sources of error. NSE is the only bio-
marker that has been recommended for prediction of
outcomes after cardiac arrest [24], but its use has been
limited by a lack of standardisation as well as diverging
cutoff levels for prediction of poor prognosis in patients
who receive hypothermia treatment and those who do not
[6]. Another major drawback of NSE is that haemolysis,
which may occur among cardiac arrest survivors, yields
falsely elevated NSE levels [25].
We could not confirm the findings from the only pre-
viously published study in which the investigators stud-
ied miRNA levels in plasma after cardiac arrest [20]. In
that prior study, miR-21 and miR-122 were put forward
as prognostic markers in a cohort of 28 patients 48 hours
after cardiac arrest. The study was small, however, and
raised some issues. First, the levels of miR-124 were not
investigated, despite being the most studied plasma
miRNA in the setting of cerebral ischemia in animal
models [17,18]. Second, microarrays were performed,
clustering 115 miRNAs, but most data derived from this
screening were not presented. Third, on the basis of an
in vitro experiment using retinoic acid–differentiated
neuroblastoma cells, the authors speculated that miR-
122 might originate in the brain. However, it is not cor-
rect to equate miR-122 expression generated by artifi-
cial differentiation with a true neural phenotype.
Furthermore, miR-122 is generally regarded as a liver-
specific miRNA, and to date no authors have reported
any significant levels of miR-122 in the human brain
[26]. In our present study, which included more pa-
tients, we are unable to confirm that miR-122 has
prognostic properties after cardiac arrest. Instead, we
found a decrease in the plasma levels of miR-122 in
both outcome groups, which is in concordance with
data in published reports on patients with myocardial
infarction as well as experiments on rats exposed to
transient brain ischemia [23,27]. Moreover, we were
not able to repeat the finding of higher levels of miR-
21 in the poor prognosis group. There are some issues
that could theoretically explain these diverging results.
In the previous study [20], the patients were matched
in respective groups with regard to age and sex,
whereas in our present study we stratified the patients
only with regard to outcomes. However, there were no
differences in age and sex between the outcome groups in
our study A technical difference is that we related the
miRNA levels to both the spike-in and baseline values
using the 2−ΔΔCt formula, whereas Stammet et al. chose to
relate only to the mean values of the spike-ins (2−ΔCt).
When we analysed our data accordingly, however, the
results were not altered. Another difference between
our study and that of Stammet et al. is that we used
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our experience, the spike-in controls vary very little in
relation to one another when added together, and we
do not believe that this aspect of the studies can ex-
plain the diverging results.
Our study has some limitations. First, the long period be-
tween tissue collection and analysis of the samples might
have affected the quality of the samples. However, miRNA
is very stable, both at room temperature and after repeti-
tive cycles of freeze-thawing. In our present study, all sam-
ples were thawed only once and stored at −80°C until the
analysis [28]. Second, a general problem in miRNA re-
search in plasma is the deficiency of well-validated en-
dogenous controls to compensate for differences in RNA
input. Regarding the cardiac arrest syndrome, the systemic
inflammatory response and secondary effects of most
organ systems makes it even more difficult to find a valid
control for RNA load. Hence, in concordance with most of
the published studies in this field, our data were not nor-
malized to RNA input.
Before plasma miR-124 can be used for prognostica-
tion in the clinical setting, several technical aspects have
to be handled. First, the preparation of samples and the
PCR technique pose some limitations. RNA preparation,
cDNA synthesis and PCR are time-consuming processes,
and the validity of the results is highly dependent on
meticulous handling of the samples. Second, in order to
minimize imprecision, well-validated controls should be
used. An endogenous control for RNA load in the set-
ting of cardiac arrest is lacking, however, and more re-
search should be focused on this area. Furthermore, it is
important to observe whether the cutoff levels are totally
dependent on both the endogenous control and the
spike-in used in a particular study. Interestingly, several
new non-PCR techniques for miRNA quantification in
plasma, such as the nanopore device and methodology,
are currently being developed and may overcome some
of these issues [29].
Conclusion
Our data suggest that the brain-enriched miRNA miR-
124 is a promising, novel biomarker for predicting the
prognosis for hypothermia-treated patients after cardiac
arrest, with a calculated ROC AUCs of 0.87 at 24 hours
and 0.89 at 48 hours. Our findings need to be validated
prospectively in a larger cohort, which we plan to do as
a substudy of the Target Temperature Management after
Cardiac Arrest Trial [30].
Key message
 The brain-enriched miRNA miR-124 is a promising,
novel biomarker for the prediction of prognosis in
hypothermia-treated patients after cardiac arrest.Additional files
Additional file 1: Supplementary materials and methods data.
Laboratory work is described in more detail.
Additional file 2: Figure S1. Screening of 20 plasma microRNAs at
48 hours after cardiac arrest. After Bonferroni correction, no significant
differences were observed between the outcome groups for any of the
microRNAs. The horizontal lines represent median values.
Additional file 3: Figure S2. MicroRNA levels at admission relative to
the spike-in Sp2. No differences between the outcome groups were
observed. The horizontal lines represent median values.
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